Changqing Xie, Austin G. Duffy, Donna Mabry‐Hrones, Bradford Wood, Elliot Levy, Venkatesh Krishnasamy, Javed Khan, Jun S. Wei, David Agdashian, Manoj Tyagi, Vineela Gangalapudi, Suzanne Fioravanti, Melissa Walker, Victoria Anderson, David Venzon, William D. Figg, Milan Sandhu, David E. Kleiner, Maria Pia Morelli, Charalampos S. Floudas, Gagandeep Brar, Seth M. Steinberg, Firouzeh Korangy, Tim F. Greten – 22 December 2018 – Treatment options for patients with advanced biliary tract cancer are limited.

Myeong‐Jin Kim, Sunyoung Lee – 21 December 2018

Hung Huynh, Liek Yeow Lee, Kah Yong Goh, Richard Ong, Huai‐Xiang Hao, Alan Huang, Youzhen Wang, Diana Graus Porta, Pierce Chow, Alexander Chung – 21 December 2018 – The fibroblast growth factor (FGF) signaling cascade is a key signaling pathway in hepatocarcinogenesis. We report high FGF receptor (FGFR) expression in 17.7% (11 of 62) of hepatocellular carcinoma (HCC) models. Infigratinib, a pan‐FGFR inhibitor, potently suppresses the growth of high‐FGFR‐expressing and sorafenib‐resistant HCCs.

Bruce Wang, Sean Rudnick, Brent Cengia, Herbert L. Bonkovsky – 20 December 2018 – The acute hepatic porphyrias (AHPs) are a group of four inherited diseases of heme biosynthesis that present with episodic, acute neurovisceral symptoms. The four types are 5‐aminolevulinic acid (ALA) dehydratase deficiency porphyria, acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria. Their diagnoses are often missed or delayed because the clinical symptoms mimic other more common disorders.

Thomas G. Cotter, Michael R. Charlton – 20 December 2018

Dominique Salmon‐Ceron, Pierre Nahon, Richard Layese, Valérie Bourcier, Philippe Sogni, Firouze Bani‐Sadr, Etienne Audureau, Laurence Merchadou, François Dabis, Linda Wittkop, Françoise Roudot‐Thoraval, for the ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups – 19 December 2018 – It is widely accepted that human immunodeficiency virus (HIV) infection is a risk factor for increased severity of hepatitis C virus (HCV) liver disease.

Elizabeth C. Goode, Allan B. Clark, George F. Mells, Brijesh Srivastava, Kelly Spiess, William T.H. Gelson, Palak J. Trivedi, Kate D. Lynch, Edit Castren, Mette N. Vesterhus, Tom H. Karlsen, Sun‐Gou Ji, Carl A. Anderson, Douglas Thorburn, Mark Hudson, Michael A. Heneghan, Mark A. Aldersley, Andrew Bathgate, Richard N. Sandford, Graeme J. Alexander, Roger W. Chapman, Martine Walmsley, UK‐PSC Consortium, Gideon M. Hirschfield, Simon M.

Katalina Funke, Don C. Rockey – 18 December 2018

Carol J. Soroka, David N. Assis, Leina S. Alrabadi, Scott Roberts, Laura Cusack, Ariel B. Jaffe, James L. Boyer – 18 December 2018 – Primary sclerosing cholangitis (PSC) is a heterogeneous and progressive fibroinflammatory cholangiopathy with no known etiology or effective treatment. Studies of PSC are limited due to difficulty in accessing the cholangiocyte, the small percentage of these cells in the liver, instability of in vitro culture systems, and reliance on samples from end‐stage disease.

Xueliang Zuo, Zhiqiang Chen, Juan Cai, Wen Gao, Yao Zhang, Guoyong Han, Liyong Pu, Zhengshan Wu, Wei You, Jianjie Qin, Xinzheng Dai, Hongbing Shen, Jindao Wu, Xuehao Wang – 18 December 2018 – Serotonin and its receptors have been shown to play critical regulatory roles in cancer biology. Nevertheless, the contributions of 5‐hydroxytryptamine 1D (5‐HT1D), an indispensable member of the serotonergic system, to hepatocellular carcinoma (HCC) remain unknown. The present study demonstrated that the 5‐HT1D expression level was significantly up‐regulated in HCC tissues and cell lines.